Erythromycin: Difference between revisions
(Text replacement - "-->" to "→") |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[Macrolide]] | ||
*Dosage Forms: | *Dosage Forms: PO, IV, topical | ||
*Common Trade Names: | *Common Trade Names: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*250-500mg PO q6h | |||
===Pre-endoscopy=== | ===Pre-endoscopy=== | ||
*3mg/kg IV over 20-30min, 30-90min prior to endoscopy | *3mg/kg IV over 20-30min, 30-90min prior to endoscopy | ||
| Line 10: | Line 12: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Mild-moderate infections: 30-50 mg/kg/day PO divided q6-8hr | |||
*Severe infection: 60-100 mg/kg/day PO divided q6-8hr | |||
==Special Populations== | ==Special Populations== | ||
*Pregnancy: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *[[Lactation risk categories|Lactation risk]]: AAP categorizes as compatible with breastfeeding | ||
*Renal Dosing | *Renal Dosing: No adjustment | ||
*Hepatic Dosing: Use caution | |||
*Hepatic Dosing | |||
==Contraindications== | ==Contraindications== | ||
| Line 27: | Line 27: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Torsades, ventricular dysrhythmias | |||
*Pseudomembranous colitis | |||
*Hypertrophic pyloric stenosis | |||
*Seizures | |||
===Common=== | ===Common=== | ||
| Line 169: | Line 173: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 19:32, 22 September 2019
General
- Type: Macrolide
- Dosage Forms: PO, IV, topical
- Common Trade Names:
Adult Dosing
- 250-500mg PO q6h
Pre-endoscopy
- 3mg/kg IV over 20-30min, 30-90min prior to endoscopy
- Achieves endoscopy conditions equal to lavage[1]
Pediatric Dosing
- Mild-moderate infections: 30-50 mg/kg/day PO divided q6-8hr
- Severe infection: 60-100 mg/kg/day PO divided q6-8hr
Special Populations
- Pregnancy Rating: B
- Lactation risk: AAP categorizes as compatible with breastfeeding
- Renal Dosing: No adjustment
- Hepatic Dosing: Use caution
Contraindications
- Allergy to class/drug
- QT prolongation
Adverse Reactions
Serious
- Torsades, ventricular dysrhythmias
- Pseudomembranous colitis
- Hypertrophic pyloric stenosis
- Seizures
Common
- nausea/vomiting
- diarrhea
- urticaria
- transaminitis
- urticarial rash
Pharmacology
- Half-life: 2 hours
- Metabolism: Liver
- Excretion: Bile/Renal
- Mechanism of Action: Binds to 50S ribosomal unit → inhibiting protein synthesis
Antibiotic Sensitivities[2]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia